Date: 06/17/2025

by: Rob Wyer

Specialist in Rare Disease Engagement | EU JCA Patient Strategy | Digital Health Innovation

Introduction: As the EU’s Joint Clinical Assessment (JCA) system rapidly evolves, patient involvement is no longer a “nice-to-have”—it’s a regulatory imperative and a strategic advantage. With orphan medicines entering the JCA process in 2028, organisations must move beyond token engagement and embed authentic patient partnership into every stage of development and assessment. Read more here https://www.linkedin.com/pulse/making-patient-partnership-living-reality-rob-wyer-y64ye/